How much have AI applications learned, and how can one know their capabilities if they are being evaluated with an exam that ...

In its fourth major biopharma deal since its 2019 founding, Repertoire Immune Medicines signed a partnership with Eli Lilly ...

Oncology-focused Eikon Therapeutics Inc. set the terms of its IPO Jan. 28, selling 17.648 million shares at a price range between $16 to $18 per share. At the top of the range, the Millbrae, ...

For years, Japan’s “drug lag” was shorthand for slow regulatory reviews and delayed approvals compared with the U.S. and Europe. But even as regulatory timelines have shortened, review capacity has ...

Six-month results from the REMAIN-1 trial showed that Fractyl Health Inc.’s Revita procedure cut post-GLP-1 weight regain by about 70% compared with a sham procedure in patients who discontinued ...

The days of the U.S. FDA considering as trade secrets country-of-origin info for drugs and their ingredients have to end, the Senate Aging Committee was told at a Jan. 29 hearing on truth in drug ...

A Jan. 28 report on Medicare spending on lab tests indicated that spending on many types of tests flattened between 2022 and 2024, but spending on genetic tests rose 20% between 2023 and 2024 to $3.6 ...

The presbyopia space gained another player as Tenpoint Therapeutics Ltd. won the U.S. FDA’s go-ahead for Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution, 2.75%/0.1%, previously known ...

Siren Biotechnology Inc. has obtained IND approval from the FDA enabling the initiation of its first-in-human trial for its lead investigational program SRN-101 in adult patients with recurrent ...

Work at Apertor Pharmaceuticals Inc. has led to the preparation of new hetero-bifunctional compounds acting as mTOR complex 1 (mTORC1) inhibitors potentially useful for the treatment of cancer.

Wuxi Biologics Co. Ltd. and Sinorda Biomedicine have established a strategic collaboration for the development and manufacturing of SND-006, a novel bispecific antibody, for the treatment of ...

Beijing Avistone Pharmaceuticals Biotechnology Co. Ltd. has patented HER2 (erbB2) Ex20Ins mutant inhibitors. They are reported to be useful for the treatment of cancer, atherosclerosis and pulmonary ...